Review article · 2020 · Open access

Phage Therapy in the Resistance Era: Where Do We Stand and Where Are We Going?

Tiffany Luong, Ann-Charlott Salabarria, Dwayne R. Roach

Clinical Therapeutics, 42(9), 1659–1680 · Published 31 August 2020 · DOI 10.1016/j.clinthera.2020.07.014

Free PDFView at the publisherCite this paper

In brief

“Phage Therapy in the Resistance Era: Where Do We Stand and Where Are We Going?” is a 2020 review article by Tiffany Luong and 2 co-authors, published in Clinical Therapeutics. OpenAlex counts 295 citations as of 15 November 2026, which puts it in the top 3% of works published in 2020 by citations. It is open access under a CC BY-NC-ND licence: the full text is free to read at Clinical Therapeutics.

Citations
295
Most cited in
2024 (66)
Field-weighted impact
3.66
References
171
Authors
3

Abstract

PURPOSE: Widespread antibiotic-resistant bacteria are threatening the arsenal of existing antibiotics. Not only are antibiotics less likely to be effective today, but their extensive use continues to drive the emergence of multidrug-resistant pathogens. A new-old antibacterial strategy with bacteriophages (phages) is under development, namely, phage therapy. Phages are targeted bacterial viruses with multiple antibacterial effector functions, which can reduce multidrug-resistant infections within the human body. This review summarizes recent phage therapy clinical trials and patient cases and outlines the fundamentals behind phage treatment strategies under development, mainly through bench-to-bedside approaches. We discuss the challenges that remain in phage therapy and the role of phages when combined with antibiotic therapy. METHODS: This narrative review presents the current knowledge and latest findings regarding phage therapy. Relevant case reports and research articles available through the Scopus and PubMed databases are discussed. FINDINGS: Although recent clinical data suggest the tolerability and, in some cases, efficacy of phage therapy, the clinical functionality still requires careful definition. The lack of well-controlled clinical trial data and complex regulatory frameworks have driven the most recent human data generation on a single-patient compassionate use basis. These cases often include the concomitant use of antibiotics, which makes it difficult to draw conclusions regarding the effectiveness of phages alone. However, human data support using antibiotics as phage potentiators and resistance breakers; thus, phage adjuvants are a promising avenue for near-term clinical development. Current knowledge gaps exist on the appropriate routes of administration, phage selection, frequency of administration, dosage, phage resistance, and pharmacokinetic and pharmacodynamic properties of the phages. In addition, we highlight that some phage therapies have mild adverse effects in patients. IMPLICATIONS: Although more translational research is needed before the clinical implementation is feasible, phage therapy may well be pivotal in safeguarding humans against antibiotic-resistant infections.

Cite this paper

Formatted from the catalogue record. Check names, capitals and page numbers against the paper before you submit.

APA 7

Luong, T., Salabarria, A.-C., & Roach, D. R. (2020). Phage Therapy in the Resistance Era: Where Do We Stand and Where Are We Going? Clinical Therapeutics, 42(9), 1659–1680. https://doi.org/10.1016/j.clinthera.2020.07.014

MLA 9

Luong, Tiffany, et al. “Phage Therapy in the Resistance Era: Where Do We Stand and Where Are We Going?” Clinical Therapeutics, vol. 42, no. 9, 2020, pp. 1659–1680. https://doi.org/10.1016/j.clinthera.2020.07.014.

Chicago

Luong, Tiffany, Ann-Charlott Salabarria, and Dwayne R. Roach. 2020. “Phage Therapy in the Resistance Era: Where Do We Stand and Where Are We Going?” Clinical Therapeutics 42 (9): 1659–1680. https://doi.org/10.1016/j.clinthera.2020.07.014.

Harvard

Luong, T., Salabarria, A.-C. and Roach, D. R. (2020) ‘Phage Therapy in the Resistance Era: Where Do We Stand and Where Are We Going?’, Clinical Therapeutics, 42(9), pp. 1659–1680. doi:10.1016/j.clinthera.2020.07.014.

IEEE

T. Luong, A.-C. Salabarria, and D. R. Roach, “Phage Therapy in the Resistance Era: Where Do We Stand and Where Are We Going?,” Clinical Therapeutics, vol. 42, no. 9, pp. 1659–1680, 2020, doi: 10.1016/j.clinthera.2020.07.014.

BibTeX

@article{luong2020phage,
  title     = {{Phage Therapy in the Resistance Era: Where Do We Stand and Where Are We Going?}},
  author    = {Luong, Tiffany and Salabarria, Ann-Charlott and Roach, Dwayne R.},
  journal   = {Clinical Therapeutics},
  year      = {2020},
  volume    = {42},
  number    = {9},
  pages     = {1659--1680},
  doi       = {10.1016/j.clinthera.2020.07.014},
  url       = {https://doi.org/10.1016/j.clinthera.2020.07.014}
}

Download for a reference manager: BibTeX (.bib) · RIS for Zotero, Mendeley and EndNote (.ris)

Citations by year

YearCitationsShare of the best year
202055
20212828
20224040
20235050
20246666
20256464
20264242

Its field-weighted citation impact is 3.66: it has been cited 3.66 times as often as the average work of the same field, type and year (1.00 is the world average).

Topic and keywords

Life Sciences › Immunology and Microbiology › Virology › Bacteriophages and microbial interactions

  • phage therapy
  • bacteriophages
  • antibiotic resistance
  • multidrug-resistant infections
  • compassionate use
  • combination antibiotic therapy
  • phage resistance
  • phage selection

Work with this paper

Most-cited papers in Immunology and Microbiology

All highly cited Immunology and Microbiology papers

Questions about this paper

How do I cite this paper in APA style?

Luong, T., Salabarria, A.-C., & Roach, D. R. (2020). Phage Therapy in the Resistance Era: Where Do We Stand and Where Are We Going? Clinical Therapeutics, 42(9), 1659–1680. https://doi.org/10.1016/j.clinthera.2020.07.014

How many times has this paper been cited?

295 times, according to OpenAlex on 15 November 2026. Google Scholar and Scopus count different sets of sources, so their numbers differ.

Is this paper free to read?

Yes. It is open access: read the free full text at Clinical Therapeutics.

Who wrote this paper?

Tiffany Luong, Ann-Charlott Salabarria, Dwayne R. Roach.

What is the DOI of this paper?

10.1016/j.clinthera.2020.07.014. The permanent link is https://doi.org/10.1016/j.clinthera.2020.07.014.

Bibliographic data from OpenAlex (CC0), last checked 15 November 2026. ResearchGuru does not host this paper; the links go to the publisher or the repository that does.